Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 12, 2023

Enfortumab Vedotin ± Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
J. Clin. Oncol 2023 Jun 27;[EPub Ahead of Print], PH O'Donnell, MI Milowsky, DP Petrylak, CJ Hoimes, TW Flaig, N Mar, HH Moon, TW Friedlander, RR McKay, MA Bilen, S Srinivas, EF Burgess, C Ramamurthy, S George, DM Geynisman, S Bracarda, D Borchiellini, L Geoffrois, JP Maroto Rey, C Ferrario, AS Carret, Y Yu, M Guseva, B Homet Moreno, JE Rosenberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading